An observational study in Kidney Transplant Rejection, T-Cell Mediated Rejection and Kidney Transplantation, sponsored by CareDx. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by CareDx · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The HistoMap AlloSure Renal Biopsies Observational Research Study (HARBOR) is a prospective, multicenter, observational cohort study of adult kidney transplant recipients undergoing a clinically indicated kidney allograft biopsy. The study will collect biospecimens and associated clinical data to support the development and evaluation of molecular approaches for assessing kidney allograft rejection. It will also examine relationships among histopathology, tissue-based gene expression profiling using HistoMap, donor-derived cell-free DNA (dd-cfDNA) measured using AlloSure, and clinical outcomes. As an observational study, HARBOR will not direct clinical care, and all diagnostic and treatment decisions will remain at the discretion of the treating clinicians in accordance with standard clinical practice.
HARBOR will include enrollment of approximately 1,250 adult kidney transplant recipients undergoing clinically indicated kidney allograft biopsies at U.S. transplant centers. The study will prospectively collect blood and tissue specimens, biopsy findings, molecular test results, and associated clinical data to support research on kidney allograft rejection.
Histopathologic findings will be assessed in relation to results from HistoMap, a tissue-based gene expression profiling assay, and AlloSure, a donor-derived cell-free DNA assay. Secondary analyses will evaluate agreement among diagnostic assessments and associations with kidney allograft function and outcomes.
Participants will be classified into two observational cohorts using index-biopsy findings and AlloSure results. All participants will undergo an assessment at Month 1. Participants meeting criteria for Cohort 1 will have additional assessments at Months 3 and 6, with a final assessment at Month 12; participants in Cohort 2 will complete study follow-up at Month 1. The study will not assign or direct treatment, and all clinical management decisions will remain at the discretion of the treating clinicians according to standard of care.
CareDx is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult kidney transplant recipients with a functioning kidney allograft undergoing a clinically indicated kidney allograft biopsy at participating U.S. transplant centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Kidney transplant recipients with rejection or related findings identified by histopathology or HistoMap, BK nephropathy on the index biopsy, or an AlloSure dd-cfDNA result ≥0.5%. Study follow-up includes assessments at Months 1, 3, and 6 after the index biopsy and an end-of-study assessment at Month 12.
Kidney transplant recipients without evidence of rejection by histopathology or HistoMap, without BK nephropathy on the index biopsy, and with an AlloSure dd-cfDNA result \<0.5%. The Month 1 assessment serves as the end-of-study visit.
Number of Unique Participants Providing Repository Specimens
Number of unique participants contributing biospecimens, summarized by specimen type and study visit.
Time frame: Index biopsy through the last protocol-specified collection, up to Month 6 after index biopsy.
Frequency and Proportion of Specimens Collected Without Nonconformities
Frequency and proportion of specimens collected and processed according to the laboratory manual without collection or processing nonconformities.
Time frame: Index biopsy through the last protocol-specified collection, up to Month 6 after index biopsy.
Frequency and Proportion of Biopsies With Associated HistoMap, AlloSure, and Additional Streck Tube Collection
Frequency and proportion of biopsies with associated tissue gene expression profiling (HistoMap), AlloSure testing, and at least one additional Streck blood tube collected.
Time frame: Through study completion (up to 12 months following index biopsy).
Frequency and Proportion of Participants With Each Kidney Rejection Type
Frequency and proportion of participants classified into each kidney rejection category based on study assessments. Rejection categories will be reported separately for histopathology and HistoMap assessments.
Time frame: Index biopsy assessment.
Clinical Performance Characteristics of HistoMap Relative to Histopathology
Clinical performance characteristics of HistoMap for classification of kidney allograft rejection relative to histopathology in a real world setting.
Time frame: Index biopsy assessment.
Concordance of Rejection Status Across HistoMap, AlloSure, and Histopathology
Concordance rate of rejection status among HistoMap, AlloSure, and histopathology assessments.
Time frame: Index biopsy assessment.
Association Between HistoMap Classification and Kidney Function
Association between index-biopsy HistoMap classification (AMR, TCMR, Mixed Rejection, or No Rejection) and kidney function as measured by estimated glomerular filtration rate (eGFR).
Time frame: Months 1, 3, and 6 post-index biopsy.
Association Between HistoMap Results and Predicted Graft Survival
Association of graft survival probabilities calculated using the iBox Prediction System across HistoMap results.
Time frame: Predicted graft survival at 3, 5, and 7 years using assessments performed at Months 3 and 6 post-index biopsy.
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CareDx